Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: CARCINOMA, NON-SMALL-CELL LUNG - DRUG THERAPY , . Treffer: 18

2015

Hilbe, W; Pall, G; Kocher, F; Pircher, A; Zabernigg, A; Schmid, T; Schumacher, M; Jamnig, H; Fiegl, M; Gächter, A; Freund, M; Kendler, D; Manzl, C; Zelger, B; Popper, H; Wöll, E Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
PLoS One. 2015; 10(5):e0125364-e0125364 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Ediebah, DE; Coens, C; Zikos, E; Quinten, C; Ringash, J; King, MT; Schmucker von Koch, J; Gotay, C; Greimel, E; Flechtner, H; Weis, J; Reeve, BB; Smit, EF; Taphoorn, MJ; Bottomley, A Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Br J Cancer. 2014; 110(10):2427-2433 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pircher, A; Manzl, C; Fiegl, M; Popper, H; Pirker, R; Hilbe, W Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Lung Cancer. 2014; 83(3): 408-410. (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2013

Olaussen, KA; Adam, J; Vanhecke, E; Vielh, P; Pirker, R; Friboulet, L; Popper, H; Robin, A; Commo, F; Thomale, J; Kayitalire, L; Filipits, M; Le Chevalier, T; André, F; Brambilla, E; Soria, JC PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Lung Cancer. 2013; 80(2):216-222
Web of Science PubMed FullText FullText_MUG

 

Shirsath, N; Rathos, M; Chaudhari, U; Sivaramakrishnan, H; Joshi, K Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Lung Cancer. 2013; 82(2):214-221
Web of Science PubMed FullText FullText_MUG

 

2011

Popper, H; Wrba, F; Gruber-Mösenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F; und die Arbeitsgruppe Pulmopathologie der ÖGP-IAP Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer.
Wien Klin Wochenschr. 2011; 123(9-10):316-321
Web of Science PubMed FullText FullText_MUG

 

Watzka, SB; Posch, F; Hochmair, M; Setinek, U; Köstler, WJ; Müller, MR Resistance to EGFR targeting therapies in lung cancer.
Minerva Chir. 2011; 66(5): 483-494.
Web of Science PubMed

 

2010

Voortman, J; Goto, A; Mendiboure, J; Sohn, JJ; Schetter, AJ; Saito, M; Dunant, A; Pham, TC; Petrini, I; Lee, A; Khan, MA; Hainaut, P; Pignon, JP; Brambilla, E; Popper, HH; Filipits, M; Harris, CC; Giaccone, G MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma.
Cancer Res. 2010; 70(21): 8288-8298. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

2009

Leithner, K; Stacher, E; Wurm, R; Ploner, F; Quehenberger, F; Wohlkoenig, C; Bálint, Z; Polachova, J; Olschewski, A; Samonigg, H; Popper, HH; Olschewski, H Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Lung Cancer. 2009; 65(1):98-104
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2007

Filipits, M; Haddad, V; Schmid, K; Huynh, A; Dunant, A; André, F; Brambilla, E; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Pirker, R Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program.
Clin Cancer Res. 2007; 13(13): 3892-3898. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Filipits, M; Pirker, R; Dunant, A; Lantuejoul, S; Schmid, K; Huynh, A; Haddad, V; André, F; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Brambilla, E Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
J Clin Oncol. 2007; 25(19): 2735-2740. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Hilbe, W; Aigner, K; Dittrich, C; Eckmayr, J; Fiegl, M; Flicker, M; Forstner, B; Greil, R; Jamnig, H; Krajnik, G; Lang, A; Mohn-Staudner, A; Schinko, H; Studnicka, M; Pirker, R; Ploner, F; Rothmund, J; Schiller, L; Zabernigg, A; Zöchbauer-Müller, S Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms
WIEN KLIN WOCHENSCHR. 2007; 119(7-8): 259-266.
Web of Science PubMed FullText FullText_MUG

 

Ploner, F NSCLC: update on second line therapy following ASCO 2007
Wien Med Wochenschr. 2007; 157(21-22): 540-544.
PubMed FullText FullText_MUG

 

2006

Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB; Swiss Group for Clinical Cancer Research (SAKK) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Br J Cancer. 2006; 94(8):1099-1106 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Hofmann, G; Bauernhofer, T; Krippl, P; Lang-Loidolt, D; Horn, S; Goessler, W; Schippinger, W; Ploner, F; Stoeger, H; Samonigg, H Plasmapheresis reverses all side-effects of a cisplatin overdose--a case report and treatment recommendation.
BMC Cancer. 2006; 6(2):1-1 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Olaussen, KA; Dunant, A; Fouret, P; Brambilla, E; André, F; Haddad, V; Taranchon, E; Filipits, M; Pirker, R; Popper, HH; Stahel, R; Sabatier, L; Pignon, JP; Tursz, T; Le Chevalier, T; Soria, JC; IALT Bio Investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
N ENGL J MED. 2006; 355: 983-991. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pohl, G; Krajnik, G; Malayeri, R; Müller, RM; Klepetko, W; Eckersberger, F; Schäfer-Prokop, C; Pokrajac, B; Schmeikal, S; Maier, A; Ambrosch, G; Woltsche, M; Minar, W; Pirker, R Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Lung Cancer. 2006; 54(1):63-67
Web of Science PubMed FullText FullText_MUG

 

2003

Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
J Clin Oncol. 2003; 21(9):1752-1759 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

© Meduni Graz Impressum